Avid Bioservices Inc (CDMO)

[cjgaddy]

BTW, the other (non-Peregrine) ESMO Late-breaker NSCLC update that was “removed” from the ESMO Program today, #LBA32/Jyoti Patel, was in ref. to a Ph.3 trial “supported by Eli Lilly”…

Added 9-19-12 to ESMO website: “Please note that abstracts LBA32 & LBA35 have been removed from the pgm.”
http://www.esmo.org/events/vienna-2012-congress/abstract-submission.html

9-8-12: “Two-Drug NSCLC Therapy Can't Boost Survival”
By Charles Bankhead, MedPage Today
http://www.medpagetoday.com/MeetingCoverage/CTS/34649
CHICAGO 9-8-12: Survival in advanced NSCLC failed to improve with pemetrexed (Eli Lilly's Alimta) vs. paclitaxel in combination chemotherapy, results of a large randomized (Ph.3) trial showed. Patients had a MOS of 12.8 mos. with the combination of pemetrexed, carboplatin, and bevacizumab (Avastin) vs. 13.4 mos. with paclitaxel, carboplatin, and bevacizumab. A modest improvement in PFS did occur in the pemetrexed arm. . .
The study was supported by Eli Lilly.
PRIMARY SOURCE: Chicago Multidisciplinary Symposium in Thoracic Oncology. . .
SOURCE REF: Patel J, et al "A randomized, open-label, phase III, superiority study of pemetrexed (Pem)+ Carboplatin (Cb)+Bevacizumab (B) followed by maintenance Pem+B vs. paclitaxel (Pac)+Cb+B followed by maintenance B in patients with stage IIIb or IV nonsquamous non-small cell lung cancer" CTS 2012; (ASTRO/Chicago)Abstract #LBPL1 [ = ESMO’12 #LBA32/removed 9-19-12 per ESMO webpage]”

= = = = = = = = = = = = = = = = = = = = =
ESMO’12 #LBA35/removed [same as 9-7-12 ASTRO/Chicago # LBPL2]:
”Randomized, double-blind, placebo-controlled phase 2 trial of Bavituximab + Docetaxel in patients with previously treated locally advanced or metastatic non-squamous NSCLC” - David E. Gerber [UTSW-MC/Dallas], Joppert, Spigel, Singh, Giorgadze, Shtivelband, Ponomarova, Joe Shan [Peregrine Pharm], Belani